SCHEMBL23476718

SCHEMBL23476718

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)S)[C@@H](O[P@](=O)(S)OC[C@@H]2C[C@@H](F)[C@H](n3cnc4c(N)ncnc43)O2)[C@H]1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NT5E P21589 1/20 0.55
▸ P2RY1 P47900 4/20 0.51
▸ P2RY2 P41231 3/20 0.51
▸ SRC P12931 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ DNPH1 O43598 1/20 0.51
▸ PRKAB2 O43741 1/20 0.51
▸ TRPM2 O94759 1/20 0.51
▸ LDHA P00338 1/20 0.51
▸ ADRB2 P07550 1/20 0.51
▸ FBP1 P09467 1/20 0.51
▸ ADORA1 P30542 1/20 0.51
▸ PRKAG1 P54619 1/20 0.51
▸ PRKAA2 P54646 1/20 0.51
▸ PDE4D Q08499 1/20 0.51
▸ KCNH2 Q12809 1/20 0.51
▸ PRKAA1 Q13131 1/20 0.51
▸ PDE3A Q14432 1/20 0.51
▸ TAS1R3 Q7RTX0 1/20 0.51
▸ TAS1R1 Q7RTX1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22080123 0.92 NT5E (0.51) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL22080564 0.92 NT5E (0.51) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL21132776 0.92 NT5E (0.54) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL18937556 0.92 RNASEL (0.60) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL18937518 0.91 P2RY1 (0.50) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL22524006 0.89 P2RY1 (0.56) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL20324624 0.89 P2RY1 (0.56) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL20224841 0.89 P2RY1 (0.56) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL21540024 0.89 P2RY1 (0.56) NT5EP2RY1P2RY2SRCSMN1; SMN2
SCHEMBL20327548 0.89 P2RY1 (0.56) NT5EP2RY1P2RY2SRCSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170043-A1 DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS CHINOOK THERAPEUTICS, INC. 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170043-A1 DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS STING1, TLR9, TLR3 NT5E 1329/4885P2RY1 1108/4885P2RY2 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback